MCID: CHL006
MIFTS: 31

Childhood Oligodendroglioma

Categories: Bone diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Childhood Oligodendroglioma

MalaCards integrated aliases for Childhood Oligodendroglioma:

Name: Childhood Oligodendroglioma 12 15
Oligodendroglioma, Childhood 71
Pediatric Oligodendroglioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3183
MeSH 43 D009837
NCIt 49 C4045
UMLS 71 C0280475

Summaries for Childhood Oligodendroglioma

MalaCards based summary : Childhood Oligodendroglioma, also known as oligodendroglioma, childhood, is related to oligoastrocytoma and anaplastic oligodendroglioma, and has symptoms including seizures and headache. An important gene associated with Childhood Oligodendroglioma is KIAA1549 (KIAA1549), and among its related pathways/superpathways are Central carbon metabolism in cancer and Cytosine methylation. The drugs Thiotepa and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and liver.

Related Diseases for Childhood Oligodendroglioma

Diseases related to Childhood Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 82)
# Related Disease Score Top Affiliating Genes
1 oligoastrocytoma 30.0 MGMT IDH2
2 anaplastic oligodendroglioma 29.8 OLIG2 MGMT IDH2
3 mixed oligodendroglioma-astrocytoma 29.3 MGMT IDH2 IDH1 ATRX
4 oligodendroglioma 28.7 OLIG2 MGMT IDH2 IDH1 FUBP1 FGFR1
5 adult oligodendroglioma 27.5 TACC1 OLIG2 MYBL1 KIAA1549 IDH2 IDH1
6 thalamic neoplasm 10.3 MYBL1 KIAA1549
7 diencephalic neoplasm 10.3 MYBL1 KIAA1549
8 frontal lobe neoplasm 10.3 MGMT IDH1
9 spinal cord glioma 10.3 KIAA1549 IDH1
10 glial tumor 10.3 OLIG2 IDH1
11 spinal cancer 10.3 KIAA1549 IDH1
12 clear cell ependymoma 10.2 OLIG2 IDH1
13 enchondroma 10.2 IDH2 IDH1
14 breast intraductal papillomatosis 10.2 IDH2 IDH1
15 intraductal papilloma 10.2 IDH2 IDH1
16 breast duct papilloma 10.2 IDH2 IDH1
17 breast papillomatosis 10.2 IDH2 IDH1
18 cytogenetically normal acute myeloid leukemia 10.2 IDH2 IDH1
19 intracranial chondrosarcoma 10.2 IDH2 IDH1
20 periosteal chondrosarcoma 10.1 IDH2 IDH1
21 spinal cord astrocytoma 10.1 MGMT KIAA1549 IDH1
22 breast hemangioma 10.1 IDH2 IDH1
23 supratentorial primitive neuroectodermal tumor 10.1 OLIG2 IDH1
24 juxtacortical chondroma 10.1 IDH2 IDH1
25 malignant ependymoma 10.1 MGMT KIAA1549 IDH1
26 spinal cord lipoma 10.1 MGMT FGFR1
27 interval angle-closure glaucoma 10.1 IDH2 IDH1
28 chondroblastic osteosarcoma 10.1 IDH2 IDH1
29 intraductal breast benign neoplasm 10.1 IDH2 IDH1
30 breast benign neoplasm 10.1 IDH2 IDH1
31 spindle cell hemangioma 10.0 IDH2 IDH1
32 d-2-hydroxyglutaric aciduria 1 10.0 IDH2 IDH1
33 2-hydroxyglutaric aciduria 10.0 IDH2 IDH1
34 adult brain stem glioma 10.0 MGMT IDH2 IDH1
35 l-2-hydroxyglutaric aciduria 10.0 IDH2 IDH1
36 pediatric meningioma 10.0 KIAA1549 FAM131B
37 gemistocytic astrocytoma 9.9 MGMT IDH2 IDH1
38 thoracic benign neoplasm 9.9 IDH2 IDH1
39 multiple enchondromatosis, maffucci type 9.9 IDH2 IDH1 ATRX
40 enchondromatosis, multiple, ollier type 9.9 IDH2 IDH1 ATRX
41 papillary craniopharyngioma 9.9 KIAA1549 FAM131B
42 visual epilepsy 9.9
43 seizure disorder 9.9
44 temporal lobe neoplasm 9.9 MGMT IDH1 FUBP1 ATRX
45 astrocytoma 9.9
46 cranial nerve palsy 9.9
47 rare tumor 9.9
48 supratentorial cancer 9.8 OLIG2 MGMT KIAA1549 IDH1
49 juvenile pilocytic astrocytoma 9.8 OLIG2 MGMT KIAA1549 IDH1
50 systemic mastocytosis 9.8 IDH2 IDH1 FGFR1

Graphical network of the top 20 diseases related to Childhood Oligodendroglioma:



Diseases related to Childhood Oligodendroglioma

Symptoms & Phenotypes for Childhood Oligodendroglioma

UMLS symptoms related to Childhood Oligodendroglioma:


seizures, headache

Drugs & Therapeutics for Childhood Oligodendroglioma

Drugs for Childhood Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 130)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
2
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
3
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
4
leucovorin Approved Phase 3 58-05-9 6006 143
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
6
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
7
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
8
Ondansetron Approved Phase 3 99614-02-5 4595
9
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
10
Histamine Approved, Investigational Phase 3 51-45-6 774
11
Cyproheptadine Approved Phase 3 129-03-3 2913
12
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
13 Antirheumatic Agents Phase 3
14 Immunosuppressive Agents Phase 3
15 Folic Acid Antagonists Phase 3
16 Vitamin B Complex Phase 3
17 Folate Phase 3
18 Antimetabolites Phase 3
19 Vitamin B9 Phase 3
20 Antiemetics Phase 3
21 Emetics Phase 3
22 Neurotransmitter Agents Phase 3
23 Histamine Antagonists Phase 3
24 Anti-Allergic Agents Phase 3
25
Histamine Phosphate Phase 3 51-74-1 65513
26 Histamine H1 Antagonists Phase 3
27 Dermatologic Agents Phase 3
28 Gastrointestinal Agents Phase 3
29
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
30
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
31
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
32
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
33
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
34
Sodium citrate Approved, Investigational Phase 2 68-04-2
35
Tamoxifen Approved Phase 2 10540-29-1 2733526
36
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
37
Promethazine Approved, Investigational Phase 2 60-87-7 4927
38
Acetaminophen Approved Phase 2 103-90-2 1983
39
Iodine Approved, Investigational Phase 2 7553-56-2 807
40
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
41
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
42
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
43
Tyrosine Approved, Investigational, Nutraceutical Phase 1, Phase 2 60-18-4 6057
44
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
45 Molgramostim Investigational Phase 2 99283-10-0
46 Immunologic Factors Phase 2
47 Alkylating Agents Phase 2
48
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
49 Anticonvulsants Phase 1, Phase 2
50
Liposomal doxorubicin Phase 2 31703

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
2 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
3 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
4 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
5 Phase II Study of the Combination of Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents at Diagnosis or in Relapse Unknown status NCT00360945 Phase 2 cisplatin;temozolomide
6 Management of Children Aged Less Than 3 Years With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
7 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
8 A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors Completed NCT00006102 Phase 2 becatecarin
9 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide
10 A Phase I/II Trial of Temodar in Pediatric Patients and Young Adults With High-Risk or Recurrent Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
11 A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva; Erlotinib Hydrochloride; OSI-774) During and After Radiotherapy in the Treatment of Patients With Newly Diagnosed High Grade Glioma and Unfavorable Low-Grade Glioma Completed NCT00124657 Phase 1, Phase 2 Erlotinib hydrochloride
12 PHASE II STUDY OF CARBOPLATIN (CBDCA) IN THE TREATMENT OF CHILDREN AND ADULTS WITH PROGRESSIVE LOW GRADE GLIOMAS Completed NCT00002749 Phase 2 carboplatin
13 A Phase II Study of Conformal Radiotherapy In Patients With Low-Grade Gliomas Completed NCT00238264 Phase 2
14 Treatment of Newly Diagnosed High-Grade Gliomas in Patients Ages Greater Than or Equal to 3 and Less Than or Equal to 21 Years With a Phase II Irinotecan Window Followed by Radiation Therapy and Temozolomide Completed NCT00004068 Phase 2 irinotecan hydrochloride;temozolomide
15 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
16 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
17 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
18 Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
19 A Phase I/II Study Of A Recombinant Chimeric Protein Composed Of Transforming Growth Factor (TGF)-a And A Mutated Pseudomonas Exotoxin Termed PE38 (TP-38) In Pediatric Patients With Recurrent Or Progressive Supratentorial High Grade Gliomas Terminated NCT00074334 Phase 1, Phase 2
20 Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study Unknown status NCT00002647 Phase 1 verteporfin
21 Phase I Trial Of Escalating Oral Doses Of SCH 66336 In Pediatric Patients With Refractory Or Recurrent Brain Tumors Completed NCT00015899 Phase 1 lonafarnib
22 Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors Completed NCT01158300 Phase 1 VEGF inhibitor PTC299
23 Phase I Study of Intrathecal Spartaject-Busulfan in Children With Neoplastic Meningitis Completed NCT00006246 Phase 1 busulfan
24 A Trial of 06-BG and BCNU in Children With CNS Tumors Completed NCT00003765 Phase 1 O6-benzylguanine;carmustine
25 A Phase I Dose Escalation Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Pediatric Patients With Advanced Solid Tumors and Lymphomas Completed NCT00004212 Phase 1 exatecan mesylate
26 A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children With Refractory Solid Tumors Completed NCT00138216 Phase 1 irinotecan hydrochloride;temozolomide;vincristine sulfate
27 Phase I Trial and Pharmacokinetic Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, on a 7 Day and 21 Day Dosing Schedule in Pediatric Patients With Refractory Solid Tumors Completed NCT00036959 Phase 1 ABT-751
28 Phase I Trial and Pharmacokinetic Study of Temozolomide and O6-Benzylguanine in Childhood Solid Tumors Completed NCT00020150 Phase 1 O6-benzylguanine;temozolomide
29 Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors Completed NCT00019630 Phase 1 doxorubicin HCl liposome
30 TREATMENT OF CHILDREN AND YOUNG ADULTS WITH RECURRENT/REFRACTORY SOLID TUMORS WITH HIGH DOSE ETOPOSIDE AND CARBOPLATIN PLUS ESCALATING DOSE CYCLOPHOSPHAMIDE, FOLLOWED BY HEMATOPOIETIC RESCUE USING AUTOLOGOUS CD34+ SELECTED BLOOD STEM CELLS: A PILOT STUDY Completed NCT00007813 Phase 1 carboplatin;cyclophosphamide;etoposide
31 Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients With Refractory Solid Tumors and Leukemias Completed NCT00030108 Phase 1 ixabepilone
32 A Phase I Study of Vinblastine in Combination With Carboplatin for Children With Newly Diagnosed and Recurrent Low-Grade Gliomas Completed NCT00352495 Phase 1 carboplatin;vinblastine sulfate
33 Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas in Pediatric Patients Completed NCT00107185 Phase 1
34 A Phase I Study Of Vaccination With Telomerase Peptide Plus GM-CSF Completed NCT00069940 Phase 1
35 A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas Completed NCT01273090 Phase 1 imetelstat sodium
36 A Pilot Study of Dose-Intensified Procarbazine, CCNU, Vincristine (PCV) for Poor Prognosis Pediatric and Adult Brain Tumors Utilizing Fibronectin-Assisted, Retroviral-Mediated Modification of CD34+ Peripheral Blood Cells With O6-Methylguanine DNA Methyltransferase Completed NCT00005796 Phase 1 lomustine;procarbazine hydrochloride;vincristine sulfate
37 A Phase I Trial and Pharmacokinetic Study of Talabostat (PT-100, Val-Boro-Pro) in Combination With Temozolomide or Carboplatin in Pediatric Patients With Relapsed or Refractory Solid Tumors Including Brain Tumors Completed NCT00303940 Phase 1 carboplatin;talabostat mesylate;temozolomide
38 Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents With Refractory Primary CNS Tumors Completed NCT00503724 Phase 1 enzastaurin hydrochloride
39 A Phase I Study of SU5416 in Pediatric Patients With Recurrent or Progressive Poor Prognosis Brain Tumors Terminated NCT00006247 Phase 1 semaxanib
40 Phase I Dose Escalation Study of N-Acetylcysteine Administered in Conjunction With Carboplatin, Cyclophosphamide, and Etoposide Phosphate BBBD, in Children With Malignant Brain Tumors Terminated NCT00238173 Phase 1 acetylcysteine;carboplatin;cyclophosphamide;etoposide phosphate;mannitol;sodium thiosulfate
41 A Phase I Study of MK-0752 in Pediatric Patients With Recurrent or Refractory CNS Malignancies Terminated NCT00572182 Phase 1 MK-0752
42 A Phase I Pharmacokinetic Optimal Dosing Study of Intraventricular Topotecan for Children With Neoplastic Meningitis Terminated NCT00112619 Phase 1 topotecan hydrochloride
43 Efficacy of Gelclair™ in Reducing the Pain of Oral Mucositis in Children and Young People With Cancer (SC 2005 07) Unknown status NCT00349024 polyvinylpyrrolidone-sodium hyaluronate gel
44 Translation Study for Children and Adolescents With Low Grade Glioma Unknown status NCT00891722
45 A Pilot Study Using Carboplatin, Vincristine And Temozolomide For Children ≤ 10 Years With Progressive/Symptomatic Low-Grade Gliomas Completed NCT00077207 carboplatin;temozolomide;vincristine sulfate
46 Metabolic Syndrome in Childhood Cancer Survivors Completed NCT00920738
47 Barriers to Patient Enrollment Onto Frontline Therapeutic Clinical Trials and Development of Intervention Strategies to Increase the Proportion of Enrollment Completed NCT00002485
48 Diagnostic and Prognostic Markers in Low-Grade Gliomas Completed NCT01004523
49 A Pharmacokinetic Participation Questionnaire Study Completed NCT00890435
50 Cooperative Multicenter Study for Children and Adolescents With Low Grade Glioma Completed NCT00276640 vincristine, carboplatin;vincristine, carboplatin, etoposide

Search NIH Clinical Center for Childhood Oligodendroglioma

Genetic Tests for Childhood Oligodendroglioma

Anatomical Context for Childhood Oligodendroglioma

MalaCards organs/tissues related to Childhood Oligodendroglioma:

40
Brain, Bone, Liver

Publications for Childhood Oligodendroglioma

Articles related to Childhood Oligodendroglioma:

# Title Authors PMID Year
1
Predictors of clinical outcome in pediatric oligodendroglioma: meta-analysis of individual patient data and multiple imputation. 61
29192869 2018
2
Outcomes and Prognostic Factors in Pediatric Oligodendroglioma: A Population-Based Study. 61
29131101 2018
3
Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences with Adult Counterparts and Other Pediatric Gliomas. 61
26206478 2016
4
Conventional and advanced (DTI/SWI) neuroimaging findings in pediatric oligodendroglioma. 61
25813856 2015
5
Well-differentiated pediatric glial neoplasms with features of oligodendroglioma, angiocentric glioma and dysembryoplastic neuroepithelial tumors: a morphological diagnostic challenge. 61
24448703 2014
6
Homozygous deletion of TNFRSF4, TP73, PPAP2B and DPYD at 1p and PDCD5 at 19q identified by multiplex ligation-dependent probe amplification (MLPA) analysis in pediatric anaplastic glioma with questionable oligodendroglial component. 61
24387276 2014
7
Disseminated oligodendroglial-like leptomeningeal tumor of childhood: a distinctive clinicopathologic entity. 61
22941225 2012
8
Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. 61
19934553 2009

Variations for Childhood Oligodendroglioma

Expression for Childhood Oligodendroglioma

Search GEO for disease gene expression data for Childhood Oligodendroglioma.

Pathways for Childhood Oligodendroglioma

Pathways related to Childhood Oligodendroglioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.64 IDH2 IDH1 FGFR1
2
Show member pathways
10.07 IDH2 IDH1

GO Terms for Childhood Oligodendroglioma

Biological processes related to Childhood Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tricarboxylic acid cycle GO:0006099 9.37 IDH2 IDH1
2 DNA methylation GO:0006306 9.32 MGMT ATRX
3 2-oxoglutarate metabolic process GO:0006103 9.26 IDH2 IDH1
4 NADP metabolic process GO:0006739 9.16 IDH2 IDH1
5 isocitrate metabolic process GO:0006102 8.96 IDH2 IDH1
6 glyoxylate cycle GO:0006097 8.62 IDH2 IDH1

Molecular functions related to Childhood Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0016616 9.26 IDH2 IDH1
2 NAD binding GO:0051287 9.16 IDH2 IDH1
3 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH2 IDH1
4 isocitrate dehydrogenase activity GO:0004448 8.62 IDH2 IDH1

Sources for Childhood Oligodendroglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....